<DOC>
	<DOC>NCT02552576</DOC>
	<brief_summary>This is a multi-centre, open-label, single-arm, phase 4, post-marketing study to further investigate the efficacy and safety of Voncento in subjects with Von Willebrand Disease (VWD) in whom treatment with a Von Willebrand Factor (VWF) product is required as on-demand therapy, for prophylactic therapy, or during surgery. Subjects will be treated with Voncento either as an on-demand regimen (eg, to treat a non-surgical spontaneous or traumatic bleeding event) or prevention regimen (eg, to prevent an anticipated bleeding event) at a dose prescribed by the Investigator in accordance with the Voncento Summary of Product Characteristics (SmPC), or with a prophylaxis regimen (regular treatment with Voncento at a frequency of 1-3 times per week). Voncento will also be given to prevent and treat any surgical bleeding events.</brief_summary>
	<brief_title>Study of VoncentoÂ® in Subjects With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Diagnosis of severe type 1, 2A, or 3 VWD where Von Willebrand Factor: Ristocetin Cofactor (VWF:RCo) is &lt;20% at screening Desmopressin acetate treatment is ineffective, contraindicated, or not available for subject (type 3 VWD subjects only). Evidence of vaccination against hepatitis A and B or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunization. Written informed consent given. Require a VWF product to control a nonsurgical bleeding (NSB) event or for ongoing prophylactic therapy. Known history or suspicion of having VWF or FVIII inhibitors Acute or chronic medical condition, other than VWD, which may affect the conduct of the study Known or suspected hypersensitivity or previous evidence of severe side effects to Voncento, VWF / FVIII concentrates, or human albumin. Participated in another interventional clinical study within 30 days before the first administration of Voncento or at any time during the study. Females who are pregnant, breastfeeding or who have a positive pregnancy test at screening Alcohol, drug, or medication abuse within 1 year before the study. Currently receiving a therapy not permitted during the study. Previous participation in a Voncento / Biostate study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>